Intensified CAR-T Manufacturing: A Path to 100+ Doses per Batch

As the industry moves toward allogeneic and off-the-shelf cell therapies, scalable and cost-effective manufacturing has become essential for commercial success. In this webinar, experts from University College London (UCL) and Sartorius present a collaborative study demonstrating a robust, intensified CAR-T manufacturing workflow capable of producing more than 100 CAR-T doses per batch while maintaining high cell viability, potency, and product quality.

You will learn from this webinar:

• Case study of the scaling up of an anti-CD19 CAR‑T manufacturing workflow from 250 mL to 2 L in single‑use stirred‑tank bioreactors, with scalable downstream processing and a serum-free medium enabling production of 100+ CAR‑T doses per batch
• A clear understanding of how implementing ATF perfusion can maximize CAR-T cell yields and support robust, high-density cultures.
• Insight into how automated bioreactor harvesting and buffer exchange influence CAR-T cell quality attributes.

Who should attend:

• Process Development and MSAT leaders and teams
• Heads / Directors of Manufacturing for cell and gene therapies
• (CDMOs) offering cell therapy services
• Allogeneic CAR‑T and cell therapy developers
• Technical Operations or CMC leaders responsible for industrializing CAR‑T processes